Neurim Pharmaceuticals has won its case against generics drug maker Mylan at the English High Court, which held that its patent for a treatment for insomnia was valid and had been infringed in a ruling handed down on December 4.
The number of potentially anticompetitive patent infringement settlements between brand drugmakers and generic competitors remained low in 2017, according to the Federal Trade Commission.
Pharmaceutical companies Illumina and Roche have been sued for allegedly infringing two patents covering the technology for non-invasive DNA testing by Maryland genetic testing company Ravgen.
Abbott Laboratories must face allegations brought by Grifols Diagnostic and a Novartis subsidiary that its HIV testing products infringe a patent covering a method to create HIV proteins using recombinant DNA.
Amgen and Teva will have to face a lawsuit accusing them of restricting competition by engineering a reverse payment designed to keep generic versions of Sensipar off the market.
Teva has urged the US Court of Appeals for the Federal Circuit to rehear its dispute with GlaxoSmithKline en banc, claiming that if the decision is upheld, “every skinny-labelled generic is at risk”.
A medical technology subsidiary of Siemens has settled a lawsuit against a former vice president, who it accused of stealing trade secrets related to heart catheter devices.
The US Immigration and Customs Enforcement has unveiled the next stage of its operation to combat a wave of fraudulent vaccines and treatments, after seizing more than $26 million in illicit proceeds from COVID-19 related products over the past six months.
The UK Competition and Markets Authority is investigating Essential Pharma over suspicions that the pharmaceutical company contravened competition law by proposing to withdraw the supply of Priadel, a lithium-based medication for bipolar disease.
The Federal Court of Australia has granted Pfizer subsidiary Wyeth’s bid for an injunction against Merck Sharp Dohme in a dispute over vaccine patents.